The Herpes Zone - What are Gential Herpes (gentialherpes)?

Gential herpes (gentialherpes) is an infection of the genitals (the vulva and vagina in women and penis in men). Gential herpes is caused by the herpes simplex virus (HSV).

The surrounding areas like the anal area, buttocks and thight, and occasionally, other parts of the body where the virus has entered the body through breaks in the skin may become affected.

There are two types of HSV, Type 1 HSV usually affects the mouth and its surrounding area but it can also affect the genitals, usually acquired after oral sex. Type 2 HSV nearly always affects the genitals and is usually acquired after vaginal or anal sex.

HSV remains in certain nerve cells of the body for life, and can produce symptoms on and off in some gential herpes infected persons. To learn more about this dreadful disease, please check on the right panel for the topic that interest you.

Viruses, Start Your Engines (Kansas City InfoZine)
Researchers find what drives one of nature's powerful, nanoscale motors

Equine Virus Concerns Racing Community (KARK Little Rock)
Heads up horse racing fans! The start of the live season at Oaklawn Park is less than 2 weeks away. But an outbreak of a common horse virus is causing some concern in the racing community- could it have an affect in hot springs ?

Quarantine lifted at Felton training barn (The News Journal)
The quarantine has been lifted on the first of two barns in Delaware isolated after a fatal case of equine herpes virus was discovered last month, the Delaware state veterinarian announced Wednesday.

Alphavax, Novartis team on herpes vaccine (The News & Observer)
Triangle biotechnology company AlphaVax signed a $20 million partnership with Swiss drugmaker Novartis to continue developing an experimental vaccine for the cytomegalovirus, a type of herpes virus.

Ranbaxy: Trouble in the US (Business Standard India)
The expected delay in the launch of Imitrex, a migraine drug, in the US market, will hurt the Rs 6,648 crore Ranbaxy Laboratories. The Street had been hoping for revenues of around $80-100 million from sales of the generic in the US.